Results 71 to 80 of about 23,536 (264)

HIV viral suppression in children and adolescents who transitioned from ritonavir‐boosted lopinavir‐ to dolutegravir‐based antiretroviral therapy in Lesotho

HIV Medicine, EarlyView.
Abstract Objectives Children and adolescents living with HIV previously taking ritonavir‐boosted lopinavir (LPV/r)‐based antiretroviral therapy (ART) have been programmatically transitioned to dolutegravir (DTG)‐based regimens in many country programs.
Jacob Blankenberger, Teresa L. F. Steffy, Tristan Lee, Thithili Makhesi, Meenakshi Bakaya, Akash Devendra, Pheello Mothepu, Lipontso Motaboli, Nadine Tschumi, Anna Klicpera, Tapiwa Tarumbiswa, Frédérique Chammartin, Lineo K. Thahane, Niklaus D. Labhardt, Jennifer A. Brown   +14 more
wiley   +1 more source

Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice

AIDS Research and Therapy, 2019
Background Long-term success of cART is possible if the regimen is convenient and less-toxic. This study assessed the efficacy and safety of switching from a first-line NNRTI or boosted PI-based regimens to RPV-based regimens among virologically ...
Sivaporn Gatechompol, Anchalee Avihingsanon, Tanakorn Apornpong, Win Min Han, Stephen J. Kerr, Kiat Ruxrungtham   +5 more
doaj   +1 more source

A systematic review of evidence on weight change following initiation of long‐acting cabotegravir for the prevention or treatment of HIV

HIV Medicine, EarlyView.
Abstract Background Weight gain is an increasingly recognized concern among people receiving antiretroviral therapy (ART) and may increase the risk of non‐communicable diseases. Integrase inhibitors (INSTIs) such as dolutegravir (DTG) have been associated with weight gain, but the metabolic effects of long‐acting cabotegravir (CAB‐LA), another INSTI ...
Jonathan Kitonsa, Ronald Komata, Wilber Ssembajjwe, Daniel Grint, Julian Robinson, Eugene Ruzagira, Robert Kalyesubula, Jaime Vera, Fiona Cresswell   +8 more
wiley   +1 more source

Characteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, China.

PLoS ONE, 2014
BackgroundNatural drug resistance is a major cause of antiviral treatment failure. The characteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province remain unclear.MethodsOne hundred and fifty HIV-1 ...
Yi Bao, Di Tian, Ying-Ying Zheng, Hong-Li Xi, Dan Liu, Min Yu, Xiao-Yuan Xu   +6 more
doaj   +1 more source

Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy. [PDF]

PLoS ONE, 2018
People with HIV are at for metabolic syndrome (MetS) and fatty liver disease, but the role of Antiretroviral therapy (ART) is poorly understood. MetS and fatty liver disease been associated with changes in adiponectin, soluble ST2 (sST2), chitinase 3 ...
Obiageli Offor, Netanya Utay, David Reynoso, Anoma Somasunderam, Judith Currier, Jordan Lake   +5 more
doaj   +1 more source

Chronic alanine aminotransferase elevation in people with HIV: Time trends over 22 years and genetic predisposition

HIV Medicine, EarlyView.
Abstract Introduction Chronic elevation of alanine aminotransferase (cALT) is common in people with HIV. Published reports on cALT prevalence time trends have not been uniform. It is unknown whether genetic background is associated with cALT in people with HIV. Methods cALT was defined as ALT levels (male, >50 U/L, female, >35 U/L) at ≥2 consecutive, 6‐
Noemi R. Simon, Carlotta Mondoka, Christian W. Thorball, Isabella C. Schoepf, Lene Ryom, Irene Abela, Charles Béguelin, Urs Führer, Helen Kovari, Catia Marzolini, Annalisa Marinosci, Christian Kahlert, Luigia Elzi, David Haerry, Matthias Cavassini, Bruno Ledergerber, Jacques Fellay, Gilles Wandeler, Philip E. Tarr, the Swiss HIV Cohort Study, IA Abela, K Aebi‐Popp, A Anagnostopoulos, E Bernasconi, A Boyd, DL Braun, HC Bucher, A Calmy, M Cavassini, SE Chaudron, A Ciuffi, G Dollenmaier, M Egger, L Elzi, JS Fehr, J Fellay, S Frigerio Malossa, CA Fux, HF Günthard, A Hachfeld, DHU Haerry, B Hasse, M Hoffmann, M Huber, D Jackson‐Perry, CR Kahlert, D Kaufmann, O Keiser, RD Kouyos, H Kovari, K Kusejko, ND Labhardt, K Leuzinger, C Marzolini, KJ Metzner, N Müller, J Nemeth, D Nicca, J Notter, P Paioni, M Perreau, A Rauch, LP Salazar‐Vizcaya, P Schmid, O Segeral, RF Speck, M Stöckle, B Surial, PE Tarr, A Trkola, G Wandeler, M Weisser, S. Yerly   +72 more
wiley   +1 more source

Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients

Journal of the International AIDS Society, 2014
Doravirine (DOR) is an investigational NNRTI (aka MK‐1439) that retains activity against common NNRTI‐resistant mutants. We have previously reported the Part 1 results from a two‐part, randomized, double‐blind, Phase IIb study in ART‐naïve HIV‐1‐positive
J. Gatell, J. Morales-Ramirez, D. Hagins, M. Thompson, A. Keikawus, C. Hoffmann, S. Rugina, O. Osiyemi, Simona Escoriu, R. Dretler, Charlotte M. Harvey, Xia Xu, H. Teppler   +12 more
semanticscholar   +1 more source

Effect of hepatitis B or C co-infection on the risk for severe NNRTI-related toxicity after ART initiation in Phnom Penh, Cambodia, 2003–2012 (N = 3089).

, 2014
a95% confidence interval given in parenthesis.bAdjusted for age, gender, baseline CD4 count, baseline body weight, type of NNRTI (efavirenz vs nevirapine), baseline liverfunction tests (serum alanine aminotransferase).cAdjusted for age, gender, baseline ...
Lay Phirum (522581), Lutgarde Lynen (300843), Johan van Griensven (333866), Sopheak Thai (333860), Kimcheng Choun (333862), Anja De Weggheleire (144112)   +5 more
core   +1 more source

Longitudinal changes in readily available inflammatory markers before and after switching to integrase inhibitor‐based antiretroviral therapy in Virologically suppressed people living with HIV: A Nationwide real‐world cohort study

HIV Medicine, EarlyView.
Abstract Background Persistent immune activation and systemic inflammation remain key features of chronic HIV infection despite sustained virological suppression under antiretroviral therapy (ART), contributing to excess non‐AIDS morbidity and mortality.
Stelios Assimakopoulos, Achilleas Stamoulopoulos, Mina Psichogiou, Varvara Vasalou, Vasileios Papastamopoulos, Antonis Papadopoulos, Georgios Adamis, Maria Chini, Simeon Metallidis, Georgios Loizos, Lydia Leonidou, Helen Sambatakou, Markos Marangos, Diamantis Kofteridis, Giota Touloumi, on behalf of AMACS, G. Adamis, M. Chini, G. Chrysos, M. Marangos, O. Katsarou, D. Kofteridis, S. Metallidis, P. Panagopoulos, N. Pantazis, A. Papadopoulos, V. Paprizos, V. Papastamopoulos, M. Psichogiou, H. Sambatakou, NV. Sipsas, G. Touloumi, G. Touloumi, N. Pantazis, C. Thomadakis, A Stamoulopoulos, A Papadopoulos, A Antoniadou, C Protopapas, D Kavatha, G Chrysos, T Nitsotolis, M Psichogiou, E Mastrogianni, G Adamis, M Astriti, MN Marangos, L Leonidou, O Katsarou, A Kouramba, NV Sipsas, A Kontos, D Basoulis, M Chini, G Tsekes, N Mangafas, S Metallidis, O Tsachouridou, Τ Chrysanthidis, V Paparizos, V Vasalou, S Kourkounti, H Sambatakou, V Papastamopoulos, G Lourida, P Panagopoulos, V Petrakis, D Kofteridis, K Alexakis, V Malikidis, H Gogos, M Psichogiou   +71 more
wiley   +1 more source

Contraception use and HIV outcomes among women initiating dolutegravir‐containing antiretroviral therapy in Kenya: a retrospective cohort study

Journal of the International AIDS Society, 2022
Introduction The rollout of dolutegravir (DTG) in low‐ and middle‐income countries was disrupted by a potential association reported with periconceptional DTG exposure among women living with HIV (WLHIV) and infant neural tube defects.
John M. Humphrey, Victor Omodi, Caitlin Bernard, Mercy Maina, Julie Thorne, Ann Mwangi, Kara Wools‐Kaloustian, Rena C. Patel   +7 more
doaj   +1 more source